New Releases from NCBI BookshelfFalls: assessment and prevention in older people and in people 50 and over at higher risk.Falls: assessment and prevention in older people and in people 50 and over at higher risk.
Post Content
Uncategorized
New Releases from NCBI BookshelfPopulation-Based Helicobacter pylori Screen-and-Treat Strategies for Gastric Cancer Prevention: Guidance on Implementation.Population-Based Helicobacter pylori Screen-and-Treat Strategies for Gastric Cancer Prevention: Guidance on Implementation.
As part of the Accelerating Gastric Cancer Reduction in Europe through Helicobacter pylori Eradication (EUROHELICAN) project, the International Agency for
Uncategorized
New Releases from NCBI BookshelfMaximising participation, adherence and continuation of falls prevention interventions: Falls: assessment and prevention in older people and people 50 and over at higher risk: Evidence review I.Maximising participation, adherence and continuation of falls prevention interventions: Falls: assessment and prevention in older people and people 50 and over at higher risk: Evidence review I.
Post Content
Uncategorized
New Releases from NCBI BookshelfBlueprint for a National Prevention Infrastructure for Mental, Emotional, and Behavioral Disorders.Blueprint for a National Prevention Infrastructure for Mental, Emotional, and Behavioral Disorders.
Mental, emotional, and behavioral (MEB) disorders, including mental illness and substance use disorders, affect every U.S. population group, community, and
Uncategorized
New Releases from NCBI BookshelfDostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency.Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency.
Post Content
Uncategorized
New Releases from NCBI BookshelfRuxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over.Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over.
Post Content
